Focus on multiple myeloma

被引：133

作者：

Mitsiades, CS ^{[1
]}

Mitsiades, N

Munshi, NC

Anderson, KC

机构：

[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA

[2] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA

来源：

CANCER CELL | 2004年 / 6卷 / 05期

关键词：

D O I：

10.1016/j.ccr.2004.10.020

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：439 / 444

页数：6

共 64 条

[1] Molecular characterization of the tumor microenvironment in breast cancer [J].

Allinen, M ;

Beroukhim, R ;

Cai, L ;

Brennan, C ;

Lahti-Domenici, J ;

Huang, HY ;

Porter, D ;

Hu, M ;

Chin, L ;

Richardson, A ;

Schnitt, S ;

Sellers, WR ;

Polyak, K .

CANCER CELL, 2004, 6 (01) :17-32

[2] Fluorescence in situ hybridization analysis of aneuploidization patterns in monoclonal gammopathy of undetermined significance versus multiple myeloma and plasma cell leukemia [J].

Ana, R ;

Dolores, TM ;

Luz, SM ;

Martín, PDA ;

Marta, MA ;

José, H ;

Jesús, MM ;

Javier, FC ;

María, SJ ;

Aglae, B ;

Fernando, SMJ ;

Alberto, O .

CANCER, 2003, 97 (03) :601-609

[3] Aetiology of bone disease and the role of bisphosphonates in multiple myeloma [J].

Ashcroft, AJ ;

Davies, FE ;

Morgan, GJ .

LANCET ONCOLOGY, 2003, 4 (05) :284-292

[4] Single versus double autologous stem-cell transplantation for multiple myeloma [J].

Attal, M ;

Harousseau, JL ;

Facon, T ;

Guilhot, F ;

Doyen, C ;

Fuzibet, JG ;

Monconduit, M ;

Hulin, C ;

Caillot, D ;

Bouabdallah, R ;

Voillat, L ;

Sotto, JJ ;

Grosbois, B ;

Bataille, R .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (26) :2495-2502

[5] Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation [J].

Avet-Loiseau, H ;

Facon, T ;

Grosbois, B ;

Magrangeas, F ;

Rapp, MJ ;

Harousseau, JL ;

Minvielle, S ;

Bataille, R .

BLOOD, 2002, 99 (06) :2185-2191

[6] American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma [J].

Berenson, JR ;

Hillner, BE ;

Kyle, RA ;

Anderson, K ;

Lipton, A ;

Yee, GC ;

Biermann, JS .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3719-3736

[7] Activating Ras mutations in patients with plasma-cell disorders: a reappraisal [J].

Bezieau, S ;

Avet-Loiseau, H ;

Moisan, JP ;

Baltaille, R .

BLOOD, 2002, 100 (03) :1101-1102

[8] A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases [J].

Body, JJ ;

Greipp, P ;

Coleman, RE ;

Facon, T ;

Geurs, F ;

Fermand, JP ;

Harousseau, JL ;

Lipton, A ;

Mariette, X ;

Williams, CD ;

Nakanishi, A ;

Holloway, D ;

Martin, SW ;

Dunstan, CR ;

Bekker, PJ .

CANCER, 2003, 97 (03) :887-892

[9] The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells [J].

Bolick, SCE ;

Landowski, TH ;

Boulware, D ;

Oshiro, MM ;

Ohkanda, J ;

Hamilton, AD ;

Sebti, SD ;

Dalton, WS .

LEUKEMIA, 2003, 17 (02) :451-457

[10] Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B [J].

Chauhan, D ;

Uchiyama, H ;

Akbarali, Y ;

Urashima, M ;

Yamamoto, K ;

Libermann, TA ;

Anderson, KC .

BLOOD, 1996, 87 (03) :1104-1112

← 1 2 3 4 5 6 7 →